+
Connext Tour
NAVITOR™
TAVI SYSTEM
TAVI

Kontrollierte Freisetzung. Hervorragende Ergebnisse.
Bereit für zukünftige Interventionen.

Durchdacht in jedem Detail.

Das Navitor-Transkatheter-Aortenklappen-Implantationssystem (TAVI-System) ist ein Vorreiter auf dem Gebiet des minimalinvasiven Herzklappenersatzes. Das Navitor TAVI-System wurde für eine stabile Positionierung, eine hervorragende Ergebnisse und bereit für zukünftige Interventionen und setzt einen neuen Standard auf dem Gebiet der TAVI.

TAVI GIPFEL BEOBACHTEN:

TAVI GIPFEL 2024  TAVI GIPFEL 2023

TAVI GIPFEL BEOBACHTEN:

TAVI GIPFEL 2024  TAVI GIPFEL 2023

Eine Klasse für sich

Das Navitor TAVI-System ist intuitiv, präzise und bietet ebenso eine exzellente Hämodynamik und Haltbarkeit für TAVI-Eingriffe. Das Design sorgt für einen schleusenlosen und optimierten Klappenersatz und macht das Navitor System zu einer bevorzugten Wahl für Kliniker:innen und Patienten:innen gleichermaßen.

Merkmale der Navitor Vision

Präzision in jedem Detail

Das Navitor Vision Klappe wurde mit akribischer Sorgfalt zum Detail entwickelt, um optimale Ergebnisse bei TAVI-Verfahren zu gewährleisten.

Offizielle Bezeichnung der Navitor Titan ist Navitor Vision 35mm

HERVORRAGENDE ERGEBNISSE IN KLINISCHEN STUDIEN | 30 TAGE1,2

ENTDECKEN SIE DIE FUNKTIONEN UND VORTEILE DES NAVITOR™ TAVI SYSTEMS.

ERFAHREN SIE MEHR ÜBER:

AORTENSTENOSE   PCR London Valves 2023   EURO PCR 2024

 

Connext
TV

NEUES AUS DER THERAPIE
VON STRUKTURELLEN
HERZERKRANKUNGEN

Mehr erfahren

CONNEXT TV

Referenzen
  1. Søndergaard L, Walton AS, Worthley SG, et al. Thirty-day and one-year outcomes of the Navitor transcatheter heart valve in patients with aortic stenosis: the prospective, multicentre, global PORTICO NG study. Eurointervention 2023;EIJ-D-22-01108. eurointervention.pcronline.com/article/thirty-day-and-one-year-outcomes-of-thenavitor-transcatheter-heart-valve-in-patients-with-aortic-stenosis-the-prospective-multicentre-global-portico-ng-study.
  2. Søndergaard, L. 30-day outcomes from a next generation TAVI device with an active sealing cuff. Presented at: EuroPCR conference; May 18–20, 2021.
  3. Pibarot P, Hahn RT, Weissman NJ, et al. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. JACC Cardiovasc Imaging. 2015;8(3):340–360.
    doi.org/10.1016/j.jcmg.2015.01.008.
  4. Frater RWM, Seifter E, Liao K, et al. Advances in Anticalcific and Antidegenerative Treatment of Heart Valve Bioprostheses. Austin, TX: Silent Partners Inc; 1997:105–114.
  5. Kelly SJ, Ogle, MF, Carlyle WC, et al. Biocompatibility and calcification of bioprosthetic heart valves. Society for biomaterials. Sixth World Biomaterials Congress Transaction. 2000;13534.
  6. Vyavahare N, Hirsch D, Lerner E, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation: efficacy and mechanisms. Circulation.
    1997;95(2):479–488. doi.org/10.1161/01.CIR.95.2.479.
  7. Vyavahare N, Hirsch D, Lerner E, et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. J Biomed Mater Res. 1998;40(4):577–585.https://doi.org/10.1002/(SICI)1097-4636(19980615)40:4%3C577::AID-JBM9%3E3.0.CO;2-C.
  8. Gross JM. Calcification of bioprosthetic heart valves and its assessment. J Thorac Cardiovasc Surg. 2003;125:S6–8. doi.org/10.1067/mtc.2003.208.
  9. Tod TJ, Dove JS. The association of bound aldehyde content with bioprosthetic tissue calcification. J Mater Sci: Mater Med. 2016;27:8.
    doi.org/10.1007/s10856-015-5623-z.
  10. Meuris B, De Praetere H, Strasly M, et al. A novel tissue treatment to reduce mineralization of bovine pericardial heart valves. JTCVS. 2018;156(1):197–206. doi.org/10.1016/j.jtcvs.2018.01.099.
  11. Data on file at Abbott. 90664679
  12. Medtronic CoreValve Evolut PRO Instructions for Use.
  13. Navitor™ TAVI System Instructions for Use.
  14. Boston Scientific ACURATE neo2 Instructions for Use.
  15. Boston Scientific iSleeve Instructions for Use.
  16. Edwards Sapien 3 Instructions for Use.
  17. Koehler Sapien 3 eSheath OD BMRI 2015.
  18. Abbott data on file 90368819.
  19. Abbott data on file 90346620.
  20. Portico™ TAVI System Instructions for Use

Indicates a third-party trademark, which is the property of its respective owner.
 

Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available)or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions.

Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

© Abbott 2024. Alle Rechte vorbehalten. 9-GE-5-14383-02 10-2024

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline